AQR Capital Management
CMPX icon

AQR Capital Management’s Compass Therapeutics CMPX Stock Holding History

AQR Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
200,428
+45,210
+29% +$261K ﹤0.01% 2731
2025
Q4 		$834K Buy
155,218
+96,070
+162% +$444K ﹤0.01% 2649
2025
Q3 		$207K Buy
59,148
+10,697
+22% +$33.8K ﹤0.01% 3247
2025
Q2 		$126K Buy
+48,451
New +$99.9K ﹤0.01% 3140

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management's CMPX Position: Q1 2026 in Review

AQR Capital Management increased its Compass Therapeutics (CMPX) stake by 29% in Q1 2026, buying an estimated $261K and bringing the position to 200,428 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2731.

AQR Capital Management first reported a position in CMPX in Q2 2025 and has held it in 4 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • AQR Capital Management held 200,428 shares of Compass Therapeutics worth $1.06M as of Q1 2026.
  • AQR Capital Management bought 45,210 Compass Therapeutics shares in Q1 2026, an estimated $261K.
  • Compass Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2731 holding.
  • AQR Capital Management first reported a position in Compass Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.